| Literature DB >> 23662051 |
Gianfranco Piccirillo1, Federica Moscucci, Matteo Pascucci, Maria Antonella Pappadà, Gaetana D'Alessandro, Pietro Rossi, Raffaele Quaglione, Daniele Di Barba, Francesco Barillà, Damiano Magrì.
Abstract
BACKGROUND ANDEntities:
Keywords: QT variability; aging; chronic heart failure; heart rate variability; sudden death
Mesh:
Year: 2013 PMID: 23662051 PMCID: PMC3646393 DOI: 10.2147/CIA.S41879
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
General characteristics of study sample
| Age, years | 64 ± 13 | 60 ± 15 | 0.452 |
| Male/female | 63/12 | 41/12 | 0.275 |
| BMI, kg/m2 | 26 ± 4 | 26 ± 3 | 0.155 |
| HR, beats/min | 66 ± 11 | 68 ± 10 | 0.329 |
| Systolic blood pressure, mmHg | 123 ± 26 | 122 ± 17 | 0.700 |
| Diastolic blood pressure, mmHg | 66 ± 15 | 75 ± 11 | 0.002 |
| Left ventricular ejection fraction, % | 40 ± 10 | 57 ± 4 | 0.0001 |
| QT, ms | 375 ± 58 | 353 ± 26 | 0.007 |
| QTBazett, ms | 389 ± 51 | 372 ± 20 | 0.017 |
| QTFridericia, ms | 384 ± 51 | 366 ± 19 | 0.008 |
| QTLilly, ms | 386 ± 51 | 361 ± 19 | 0.011 |
| QTFramingham, ms | 385 ± 51 | 368 ± 18 | 0.012 |
| NYHA class, I/II/III | 10/46/19 | 0 | 0.0001 |
| Serum K+ mmEq/L | 4.2 | 4.1 | 0.842 |
| β-blockers | 35 | 0 | 0.0001 |
| Furosemide | 33 | 0 | 0.0001 |
| ACEi/Sartans | 56 | 5 | 0.0001 |
| Spironolactone | 22 | 0 | 0.0001 |
| Digoxin | 13 | 0 | 0.0001 |
| Amiodarone | 11 | 0 | 0.017 |
Note: Data are expressed as means ± standard deviation.
Abbreviations: BMI, body mass index; HR, heart rate; NYHA, New York Heart Association; ACEi, angiotensin converting enzyme; ms, milliseconds; mmEq/L milliequivalents per liter.
Mean age of subjects in the three age-subgroups
| ≤50 years | 46 ± 4 (n = 19) | 44 ± 3 (n = 17) | 0.371 |
| >50 ≤ 65 years | 58 ± 3 (n = 21) | 57 ± 4 (n = 18) | 0.342 |
| ≥65 years | 75 ± 6 (n = 35) | 77 ± 4 (n = 18) | 0.317 |
Note: Data are expressed as means ± standard deviation.
RR interval and QT dynamics data according to age and presence of chronic heart failure
| RR mean, ms | 899 ± 154 | 945 ± 142 | 0.354 | 918 ± 140 | 906 ± 127 | 0.785 | 966 (164) | 873 (126) | 0.040 |
| RR variance, ms2 | 574 (1124) | 1627 (2244)[ | 0.0001 | 805 ± 1309 | 885 ± 990 | 0.349 | 611 (820) | 580 (1340) | 0.992 |
| QT mean, ms | 363 ± 42 | 359 ± 30 | 0.801 | 371 ± 57 | 355 ± 31 | 0.294 | 385 ± 66 | 347 ± 18 | 0.008 |
| QT variance, ms2 | 36 (84) | 18 (14) | 0.066 | 43 (76) | 19 (10) | 0.011 | 38 (67) | 14 (52) | 0.004 |
| Te mean, ms | 85 ± 29 | 86 ± 13 | 0.847 | 81 ± 18 | 87 ± 22 | 0.402 | 91 ± 43 | 70 ± 13 | 0.019 |
| Te variance, ms2 | 23 (80) | 20 (16) | 0.397 | 38 (85) | 17 (33) | 0.349 | 33 (80) | 39 (35) | 0.696 |
Notes: Data are expressed as median and interquartile range (75th–25th).
P < 0.05 Group 1 vs Group 2;
P < 0.05 Group 1 vs Group 3;
P < 0.05 Group 2 vs Group 3;
P < 0.001 Group 2 vs Group 3.
Abbreviations: CHF, chronic heart failure; TeVI, Tpeak-Tend variability index; RR mean or variance, waves interval; ms, milliseconds; QT interval mean or variance.
QT variability indices according to age and presence of chronic heart failure
| QTVI | −0.40 (1.00) | −1.22 (0.35)[ | 0.0001 | −0.54 (0.88) | −1.09 (0.28) | 0.001 | −0.38 (0.90) | −0.77 (0.62) | 0.033 |
| TeVI | 0.96 (1.00) | 0.20 (0.66) | 0.003 | 0.72 (1.02) | 0.47 (0.69) | 0.133 | 0.77 (1.38) | 1.12 (0.72) | 0.551 |
| QT/RR STV60 | 0.49 (0.58) | 0.17 (0.63) | 0.002 | 0. 38 (0.75) | 0.27 (0.46) | 0.438 | 0.53 (0.70) | 0.37 (0.51) | 0.393 |
| Te/RR STV60 | 0.54 (1.28) | 0.26 (0.28) | 0.030 | 0.31 (0.65) | 0.33 (0.52) | 0.982 | 0.48 (0.81) | 0.58 (0.79) | 0.794 |
| QT/RR STVT | 0.59 (0.38) | 0.18 (0.20) | 0.001 | 0.40 (0.33) | 0.31 (0.21) | 0.256 | 0.44 (0.62) | 0.47 (0.71) | 0.460 |
| Te/RR STVT | 0.53 (1.09) | 0.25 (0.26) | 0.022 | 0.37 (0.36) | 0.33 (0.34) | 0.707 | 0.46 (0.76) | 0.81 (1.11) | 0.223 |
Notes: Data are expressed as median and interquartile range (75th–25th).
P < 0.05 Group 1 vs Group 2;
P < 0.05 Group 1 vs Group 3;
P < 0.001 Group 1 vs Group 3;
P < 0.05 Group 2 vs Group 3;
P < 0.001 Group 2 vs Group 3.
Abbreviations: QTVI, QT variability index; TeVI, Tpeak-Tend variability index; STV, short term variability.
Figure 1Relationship between QT variability index (QTVI) or Tpeak-Tend variability index (TeVI) and age in healthy control subjects.
Abbreviation: QT, from the Q wave to the T wave end.
Figure 2Relationship between age and ratio of short-term QT or Tpeak-Tend (Te) variability (STV) and resting rate (RR) variability indices, calculated on 60 consecutive beats (QT/RR STV60, Te/RRv STV60) or on 5-minute electrocardiogram recordings (QT/RR STVT, Te/RRv STVT) in healthy control subjects.
Abbreviations: QT, from the Q wave to the T wave end; v, variance.
Figure 3Relationship between age and the resting rate (RR) variability indices (ratio denominator of QTVI, TeVi, and short-term variability [STV], see Methods section), calculated on 5-minute electrocardiogram recordings (RRvariance/RRmean2 and RR STVT) or on 60 consecutive QRSs (RR STV60) in healthy control subjects.
Abbreviations: TeVI, Tend Variability index; Q-T, waves interval.
Figure 4Relationship between age and Te variance/Te mean2 (ratio numerator of Tpeak-Tend variability index, see Methods section).
Notes: No significant relation was reported between age and QTvariance/QTmean2 (ratio numerator of TeVI, see Methods section) in healthy control subjects. Abbreviations: TeVI, Tend Variability index; Q-T, waves interval.